Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

European Commission Expands Ravulizumab-cwvz Approval in Paroxysmal Nocturnal Hemoglobinuria With Pediatric Indication

September 3rd 2021

The European Commission has granted an expanded approval to ravulizumab-cwvz to include children with a body weight of at least 10 kg, as well as adolescents, with paroxysmal nocturnal hemoglobinuria.

Dr. Herrera on the Utility of CAR T-Cell Therapy in Hematologic Cancers

September 3rd 2021

Alex Herrera, MD, discusses the utility of CAR T cells in patients with hematologic cancers.

Unmet Needs in MDS

September 2nd 2021

Yazan Madanat, MD, and Mikkael A. Sekeres, MD, highlight unmet needs in the treatment of patients with high-risk MDS.

MDS: Clinical Primary Endpoints

September 2nd 2021

Experts in the treatment of MDS explore clinically meaningful treatment endpoints, including complete responses, bone marrow complete responses, and overall survival outcomes in MDS.

Pevonedistat/Azacitidine Misses EFS End Point in Frontline Higher-Risk MDS/CMML, Low-Blast AML

September 2nd 2021

The combination of pevonedistat plus azacitidine as a frontline treatment for patients with higher-risk myelodysplastic syndromes, chronic myelomonocytic leukemia, and low-blast acute myeloid leukemia did not achieve predefined statistical significance for the primary end point of event-free survival in the phase 3 PANTHER trial.

Evolving Treatment Approaches Pre- and Post-Transplant

September 2nd 2021

Vinod Pullarkat, MD, leads a detailed discussion on evolving treatment approaches using MRD pretransplant, and panelists consider recent therapeutic advances for the post-transplant setting.

5-Year Follow-up Data on CPX-351 for AML

September 2nd 2021

A panel of specialists in hematology oncology review the 5-year follow-up data on the use of CPX-351 for adults and pediatric patients with acute myeloid leukemia.

FDA Approves Zanubrutinib in Waldenström Macroglobulinemia

September 1st 2021

The FDA has approved zanubrutinib for the treatment of adult patients with Waldenström macroglobulinemia.

Paving the Way to Modern Cancer Therapy

September 1st 2021

When George P. Canellos, MD, first joined the field of oncology in the 1960s, many of his peers thought he was making huge mistake.

Dr. Murthy on the Potential Benefits of Treatment De-Escalation in Ph+ B-ALL

August 31st 2021

Guru Subramanian Guru Murthy, MD, MS, discusses the potential benefits of treatment de-escalation in Philadelphia chromosome–positive B-cell acute lymphoblastic leukemia.

Sekeres Previews Potential Combination Strategies in HR-MDS

August 30th 2021

Dr. Sekeres discusses the current unmet needs of patients with higher-risk myelodysplastic syndromes receiving hypomethylating agents, the potential utility of novel combinations in development, and the incorporation of other end points beyond overall survival in clinical trials.

Co-occurring 22q11.22 Deletions and IKZF1 Alterations Linked With Poor Outcomes in Pediatric B-ALL

August 30th 2021

Co-occurring focal 22q11.22 deletions and IKZF1 alterations were associated with inferior outcomes vs IKZF1 alterations alone in pediatric patients with B-cell acute lymphoblastic leukemia.

Risk Stratification and Patient Classification for PMF

August 30th 2021

Aaron Gerds, MD, MS, provides insight on determining low- vs high-risk primary myelofibrosis, the role of molecular status on treatment, and his approach toward symptom burden assessment.

Overview of Primary Myelofibrosis

August 30th 2021

Srdan Verstovsek, MD, PhD, describes the classic signs and symptoms of primary myelofibrosis (PMF), along with goals of therapy.

Arguing for Better Leukemia Care

August 30th 2021

Susan M. O’Brien, MD always knew medicine was the field for her. Growing up in a house full of bankers and finance-oriented family members couldn’t deter her from her chosen path.

Emerging Strategies in the Management of Relapsed/Refractory CLL

August 30th 2021

Considerations for the future treatment landscape of relapsed/refractory CLL, in light of emerging practices and clinical trial data.

Therapeutic Sequencing Strategies in Relapsed/Refractory CLL

August 30th 2021

Experts detail optimal sequencing strategies when patients with relapsed/refractory CLL move on to the next line of therapy.

Key Clinical Data in Relapsed/Refractory CLL

August 30th 2021

An in-depth analysis of current therapeutic options in relapsed/refractory chronic lymphocytic leukemia.

Unmet Needs in High-Risk MDS

August 27th 2021

The panel of experts highlight promising clinical trials for the treatment of myelodysplastic syndrome.

Ibrutinib Shows Continued Activity in Relapsed, Variant-Type Hairy Cell Leukemia

August 27th 2021

Ibrutinib demonstrated encouraging clinical responses in patients with variant-type, high-risk hairy cell leukemia.